Abstract
Purpose The selection of safe and efficacious anticancer regimens for treatment of broadly refractory patients with metastatic cancers remains a clinical challenge. Such patients are often fatigued by toxicities of prior failed treatments and may have no further viable standard of care treatment options. Liquid Biopsy-based multi-analyte profiling in peripheral blood can identify a majority of drug targets that can guide the selection of efficacious combination regimens.
Patients and Methods LIQUID IMPACT was a pilot clinical study where patients with advanced refractory cancers received combination anticancer treatment regimens based on multi-analyte liquid biopsy (MLB) profiling of circulating tumor biomarkers; this study design was based on the findings of prior feasibility analysis to determine the abundance of targetable variants in blood specimens from 1299 real-world cases of advanced refractory cancers.
Results Among the 29 patients in the intent to treat (ITT) cohort of the trial, 26 were finally evaluable as per study criteria out of whom 12 patients showed Partial Response (PR) indicating an Objective Response Rate (ORR) of 46.2% and 11 patients showed Stable Disease (SD) indicating the Disease Control Rate (DCR) to be 88.5%. The median Progression-Free Survival (mPFS) and median Overall Survival (mOS) were 4.3 months (95% CI: 3.0 – 5.6 months) and 8.8 months (95% CI: 7.0 – 10.7 months), respectively. Toxicities were manageable and there were no treatment-related deaths.
Conclusion The study findings suggest that MLB could be used to assist treatment selection in heavily pretreated patients with advanced refractory cancers.
Competing Interest Statement
Rajnish Nagarkar has no competing interests; Darshana Patil, Dadasaheb Akolkar, Navin Srivastava, Vineet Datta, Sanket Patil, Sachin Apurwa, Ajay Srinivasan, are employees of the Study Sponsor; Rajan Datar is the founder of the Study Sponsor.
Clinical Trial
CTRI/2019/02/017548
Funding Statement
No external funding was obtained for this study. The entire study was funded by the Study Sponsor (DCG).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Considerations The Liquid Impact Prospective Study was approved by institutional review boards and ethics committees of the study sponsor (Datar Cancer Genetics, DCG) as well as clinical trial site (HCG Manavata Cancer Centre, HCG-MCC). The approval letter is available at: http://ctri.nic.in/Clinicaltrials//WriteReadData/ethic/7396280324DCGLEthicsCommitteeLetter.pdf http://ctri.nic.in/Clinicaltrials//WriteReadData/ethic/79159917MCRIEthicsCommitteeLetter.pdf The trial was conducted in accordance with ethical guidelines and the Declaration of Helsinki. All study participants were previously counselled regarding study objectives as well as potential benefits and potential risks of the study. Written informed consent was obtained from all enrolled participants prior to enrollment. All study participants consented for publication of deidentified biological data. The present manuscript does not contain any personal or identifiable information or data of any participant.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Research Support This study did not receive any public or governmental funding or support. The study was wholly supported by the Sponsor, Datar Cancer Genetics (Pvt) Ltd.
Data Availability
All data pertaining to the studies described in this manuscript are provided in the manuscript and the supplementary material. There are no additional datasets.
Abbreviations
- ADL
- Activities of Daily Living
- C-ETACs
- Circulating Ensembles of Tumor Associated Cells
- CNV
- Copy Number Variations
- CR
- Complete Response
- C-TACs
- Circulating Tumor Associated Cells
- CTCs
- Circulating Tumor Cells
- DCR
- Disease Control Rate
- ECOG
- Eastern Co-operative Oncology Group
- EGFR
- Epidermal Growth Factor Receptor
- ER
- Estrogen Receptor
- ERBB2
- Erb-B2 Receptor Tyrosine Kinase 2
- ETA
- Encyclopedic Tumor Analysis
- FDA
- Food and Drug Administration
- FDG PET-CT
- 18F-Fluorodeoxyglucose Positron Emission Tomography– Computed Tomography
- HER2
- Human Epidermal Growth Factor Receptor 2
- HPE
- Histopathological Evaluation
- ICC
- Immunocytochemistry
- IHC
- Immunohistochemistry
- IRB
- Institutional Review Boards
- ITT
- Intent To Treat
- MLB
- Multi-analyte Liquid Biopsy
- mTOR
- mechanistic Target Of Rapamycin
- MTB
- Multidisciplinary Tumor Board
- NCI-CTCAE
- National Cancer Institute-Common Terminology Criteria for Adverse Events
- NCI-MATCH
- National Cancer Institute-Molecular Analysis for Therapy Choice
- NGS
- Next-Generation Sequencing
- ORR
- Objective Response Rate
- OS
- Overall Survival
- PET-CT
- Positron Emission Tomography– Computed Tomography
- PFS
- Progression Free Survival
- PIK3CA
- Phosphatidylinositol-4, 5-Bisphosphate 3-Kinase Catalytic Subunit Alpha
- PR
- Partial Response
- QoL
- Quality of Life
- RCC
- Renal Cell Carcinoma
- RECIST
- Response Evaluation Criteria in Solid Tumors
- SD
- Stable Disease
- SNV
- Single Nucleotide Variations
- SoC
- Standard of Care
- TAPUR
- Targeted Agent and Profiling Utilization Registry
- TR-AE
- Therapy Related Adverse Events
- VEGF
- Vascular Endothelial Growth Factor
- VEGFR
- Vascular Endothelial Growth Factor Receptor
